2 results match your criteria: "Wills Eye Hospital and Sidney Kimmel Medical College of Thomas Jefferson University[Affiliation]"
Efficacy and Safety of Intravitreal Gene Therapy for Leber Hereditary Optic Neuropathy Treated within 6 Months of Disease Onset.
Ophthalmology
May 2021
Centre Hospitalier National d'Ophtalmologie des Quinze Vingts, Paris, France; Sorbonne Université, INSERM, CNRS, Institut de la Vision, Paris, France; Fondation Ophtalmologique A. de Rothschild, Paris, France; Department of Ophthalmology, The University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania; CHNO des Quinze-Vingts, Institut Hospitalo-Universitaire FOReSIGHT, INSERM-DGOS CIC, Paris, France.
Purpose: To evaluate the efficacy of a single intravitreal injection of rAAV2/2-ND4 in subjects with visual loss from Leber hereditary optic neuropathy (LHON).
Design: RESCUE is a multicenter, randomized, double-masked, sham-controlled, phase 3 clinical trial.
Participants: Subjects with the m.
One-sided triangle: A case of double vision.
Surv Ophthalmol
November 2018
Department of Neuro-Ophthalmology, Wills Eye Hospital and Sidney Kimmel Medical College of Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
A 51-year-old woman presented with acute diplopia and was found to have ptosis and complete bilateral external and internal ophthalmoplegia. She had normal reflexes and gait. Serological testing showed elevated levels of GQ1b ganglioside autoantibodies, making the diagnosis of Miller Fisher syndrome.
View Article and Find Full Text PDF